

ESFRI European Research Infrastructure

- Facilities, resources and services used by the research communities to **conduct research** and **foster innovation** in their fields.
- Major scientific equipment (or sets of instruments), knowledgebased resources such as collections, archives and scientific data, e-infrastructures

European Research Infrastructure Consortium



- A European joint-venture (also allows the participation of non-European countries)
- A legal capacity recognised in all EU Member States
- Flexibility to adapt to specific requirements of each infrastructure
- Part of wider ESFRI community
- Exemptions from VAT and excise duty


EATRIS is an ERIC since Jan 2014

RI role in Europe

- High quality state of the art facilities and resources across Member States
- Professional access and services (to researchers)
- **Capacity utilization** (EU-wide long term planning)
- Mandate to tackle systemic issues such as:
 - Reproducibility
 - Standardisation and harmonization
 - Improving our ability to generate knowledge & innovation


Broken biomedical innovation pipeline

Spending on non-reproducible



Scannell et al Nat Rev Drug Disc (2012)

Failing too late in development



Adapted from Paul et al; Nat Rev Drug Disc (2010)

Translational Medicine

Phase III

Right target

- Strong link between target and disease
- Differentiated efficacy
- Available and predictive biomarkers

Right tissue

- Adequate bioavailability and tissue exposure
- Definition of PD biomarkers
- Clear understanding of preclinical and clinical PK/PD
- Understanding of drug–drug interactions

Right safety

- Differentiated and clear safety margins
- Understanding of secondary pharmacology risk
- Understanding of reactive metabolites, genotoxicity and drug-drug interactions
- Understanding of target liability

Right patient


- Identification of the most responsive patient population
- Definition of risk-benefit for a given population

Right commercial potential

- Differentiated value proposition versus future standard of care
- Focus on market access, payer and provider
- Personalized health-care strategy, including diagnostics and biomarkers

Figure 1 | The 5R framework. Summary of the key features of the five-dimensional framework: the right target, right tissue, right safety, right patient and right commercial potential. PD, pharmacodynamic; PK, pharmacokinetic.

Nat. Rev. Drug Discovery 2018



Bench to bedside and back



To perform translational research

- Create multi-disciplinary teams per project requirements
- Bring together deep understanding of the biology and the clinical presentation
- Use latest validated analytical technologies

For a better mechanistic understanding of the disease and potential therapeutic

Translational research in academia

- From deep, intra-disciplinary exploration to **multi-disciplinary**, confirmatory research
- From open question to **goal orientation**
- Many factors beyond the scientific concept dictate success:
 - Creating a product that fits the **clinical** workflow
 - Convincing **industry** that the product represents value
 - Convincing the **regulators** that the product is safe and efficacious
 - Convincing the **payors** that the product is cost-effective
 - Convincing doctors that the product addresses the medical need

The path to the patient – in a reverse approach







Vision

Making translation of scientific discoveries into medical products more effective to improve human health and quality of life.

Mission


To support researchers in developing their biomedical discoveries into **novel translational tools and interventions** for better health outcomes for society.


Supporting academia, industry, patients and policy makers

EATRIS approach


We make the translational community accessible to researchers

- Access to quality research infrastructure services
- Support multi-disciplinary, patient-oriented research
- Ensure optimal methodological approach - best infrastructure & resources
- Easy access to industry.









Coordination & Support Team































Amsterdam

NL





EATRIS Product Platforms

Imaging & Tracing





Cyril Poupon Neurospin Paris, FR

Bert Windhorst VU Medical Center Amsterdam, NL

 \rightarrow 34 institutions. (8 countries)

Vaccines

ATMP & Biologicals





Miguel Chillon

VHIR. ES

Maria Cristina Galli ISS. IT

 \rightarrow 38 institutions, (9 countries)

Small Molecules





Jan Langermans Lucia Gabriele **BPRC. NL** ISS. IT \rightarrow 15 institutions, (6 countries)



Mario Salmona Alfredo Budillon IRF Mario Negri Milan, IT INT Pascale, Napels, IT

 \rightarrow 26 institutions, (10 countries)

Biomarkers









Alain van Gool Radboudumc. TNO. NL

Laura Bermejo Andreas Scherer Sulev Koks **IRYCIS, ES** FIMM, FI Tartu University EE

 \rightarrow 49 institutions – 9 countries

Coordination & Support








Florence Bietrix David Morrow Martin de Kort

What do we do?

- User access to EATRIS research & expert services
 - Academic, industry and funders are users
- Develop new research tools
 - EATRIS Strategic Research & Innovation Agenda
- Education & Training
- Improve conditions for translation
 - New funding and collaboration models
 - EATRIS Quality initiative reproducibility

EATRIS Client Portfolio 2014 - 2018 (n =



SME (46)

- Large Pharma (15)
- Funder (22)
- Academia (79)

EATRIS Quality Initiative

Imaging and Tracer Platform

- Europ. Soc. Mol. Imaging (ESMI) Study Group focused on the standardization of small animal imaging.
- Collaborating with <u>EANM</u> and <u>EARL</u>, jointly <u>developing</u> a 89Zr PET/CT accreditation program for the calibration of scanners to enable multi-site clinical imaging trials

Vaccines platform:

 Activities towards providing reference reagents in vaccine development (EURIPRED; a knowledge infrastructure across Poverty Related Diseases)

Small molecules platform:

HTS Ring-testing (activity within "Translation together); phase 0 finalized; phase 1 involves 13 sites

Biomarker platform:

- SEQC2 (Sequencing quality control)
- ctDNA-reference material: possible collaboration with US-consortium

Medical Research Infrastructure Alliance



Operational roles

What is the role of the Amsterdam **coordination unit**?

- Professionalising access
- Coordinating key projects (SRIA)
- Tackling systemic issues; i.e for EATRIS:
 - Reproducibility
 - Standardisation and harmonisation
 - Capacity utilisation EU-wide long range planning?
 - Improving framework conditions for knowledge generation and innovation

Operational roles

What is the role of the **node/national consortium**?

- Coordinate national consortium & with C&S
- Providing access
- Executing intra- & extra- mural research
- Embedding in national eco-system
 - Collaborate with other infras, healthcare providers, NCAs etc.

National Coordination

- **Partner finding** for grant proposal preparation: Enhances Country participation in EATRIS-led grant applications
- **Community structuring** building national community cohesion and collaboration through interaction with research and infrastructure partners (including other RIs) and institutions
- **Outreach and business development** attending local industry partnering events, conferences, workshops to raise awareness of national and European EATRIS services
- Supporting local community in EC grant preparation Coordinating and leading input into projects, initiatives
- Facilitating local events, workshops and governance meetings for the European EATRIS community

For EATRIS to be successful

It takes commitment and effort from everyone

- **Be responsive** read the Platform updates, read and answer mails that are relevant, attend meetings and teleconferences
- **Be proactive** try to find colleagues that are relevant for matchmaking and other opportunities
- **Be creative** the SRIA is a home for your great translational science use it
- **Be communicative** share the EATRIS message, disseminate in your institute and research community



Benefits of EATRIS membership

- membership
 Academic support we offer a range of support services and resources to optimize your project (proposal)
- Industry partnering active company client portfolio, support in reaching out to industry
- National infrastructure funding
- New communities develop new collaborations across disciplines, sectors, countries and continents





Supporting your funding applications

Four levels of EATRIS C&S support

- 1. Consortium Building: to help with consortium building identification of relevant institutions list provided to PI, who contacts the institution(s)
- 2. Letter of support: for translational proposals and of high scientific quality
- 3. Provide services with EATRIS-ERIC as partner (i.e innovation management and industry partnering; Regulatory service; Translational Assessment Service...)
- 4. Leading role in proposal development for projects identified as flagship

Level 1: Consortium Building

- EATRIS can help you find the right European academic partner for your consortium thanks to a comprehensive database of the high-end capabilities and expertise of 90 top tier member institutions.
- This service is offered free of charge to any party (EATRIS members and non-members).
- If you are a member of the infrastructure, EATRIS can also support you to identify companies, charities or patient organisations for your consortium.

What are the criteria to benefit from EATRIS support for consortium building?

- The scope of the proposal idea must be translational;
- The PI is looking for areas of expertise and/or facilities that are crucial for project implementation.

Level 2: Letter of support

What are the criteria to obtain a letter of support from EATRIS?

- The scope of the proposal must be translational and of high scientific quality;
- The proposal must be in line with EATRIS mission: "To support researchers in developing their biomedical discoveries into novel translational tools and interventions for better health outcomes for society";
- The consortium must be multidisciplinary with laboratory and clinical expertise represented; and when relevant, industry and/or patient organisations included as partners;
- The consortium must include institutions leading in their field and/or close collaborators of EATRIS (academic members or strategic partners);
- The proposal must explicitly commit to compliance with FAIR principles and include data management plan as a project's deliverable.

Level 3: Joining as partner

- Proposals must meet criteria listed for level 2;
- EATRIS participation would clearly add value to the consortium and the proposal is consistent with EATRIS project portfolio;
- At least one EATRIS member institution participates in the proposal as partner or linked third party of EATRIS;
- The consortium is looking for "standard" type of services: e.g. regulatory expertise, HTA support, sustainability planning, industry partnering, access to training opportunities (provided by EATRIS Coordination Office in Amsterdam)

Level 4: Leading strategic projects

• From time to time, EATRIS will take a leading role in supporting the development and management of proposals coming from EATRIS member institutes, and identified as key potential contributions to the <u>EATRIS Strategic Research and Innovation Agenda</u>.

The proposal must fulfil the criteria mentioned for other levels and the following:

- The proposal idea is in line with EATRIS mission and with EATRIS Strategic Research and Innovation Agenda 2019-2022;
- The proposal is coordinated by an EATRIS institution;
- The proposal serves the research community by addressing systemic inefficiencies in medical research;
- The infrastructure can rely on strong expertise of many member institutions as project partners;
- The proposal is disruptive and will have a high impact on improving a translational pipeline, and therefore on the European Research Area.

Services provided by EATRIS as partner

Innovation Management & industry partnering

• Activities can include: design of the dissemination and exploitation plan of the project; definition and implementation of a monitoring plan to capture intellectual property protection needs in a timely fashion; identification of industry partnering opportunities for co-development and/or out-licensing; follow-up financing opportunities.

Translational optimisation

 Activities can include: monitoring of the project to ascertain a timely evaluation of the translational potential of the results generated during the project; full translational assessment to define followup validation route; early Health Technology Assessment (HTA) support.

Regulatory support

- Assessing the project's regulatory strategy and feasibility;
- Interacting with the relevant regulatory authorities;
- Answering any regulatory question arising during the project's lifetime;
- Ensuring the project fulfils all regulatory requirements

The EATRIS Platforms

EATRIS BIOMARKER PLATFORM

63 European advanced biomarker development centres

State-of-the-art technologies and expertise:



- Biobanks and associated medical data
- Liquid Biopsy
- Assay development and validation
- Clinical expertise
- Multi-centre clinical trials prospective validation
- Handover to industry early dialogue & partnering
- Regulatory and reimbursement

EATRIS BIOMARKER PLATFORM – Technology offering

Omics - technologies and bioinformatics:

- Genomics, next-gen DNA/RNA sequencing
- Proteomics, metabolomics...



Molecular pathology

- Multiplexed immunoassays and immunostaining of cells/tissues/TMAs
- Antibody libraries, antibody engineering and immunoassay development
- Automated images analysis and web microscopy

Targeted mass spectrometry

Multiparametric flow cytometry

COLLABORATING TOWARDS GOOD BIOMARKER PRACTICES





European infrastructure for translational medicine









COMMENT

Bridging the translational innovation gap through good biomarker practice

Alain J. van Gool¹, Florence Bietrix², Eric Caldenhoven³, Kurt Zatloukal⁴, Andreas Scherer⁵, Jan-Eric Litton⁶, Gerrit Meijer⁷, Niklas Blomberg⁸, Andy Smith⁸, Barend Mons⁹, Jaap Heringa¹⁰, Wim-Jan Koot³, Martin J. Smit¹¹, Marian Hajduch¹², Ton Rijnders³ and Anton Ussi²


Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.

{{Nature Reviews Drug Discovery, Apr 2017}



COST action CA16113 http://clinimark.eu

DEFRAGMENTING BIOMARKER VALIDATION CAPACITIES



Join forces among Europe's major academic infrastructures + industry to:

1. Establish "Good Biomarker Practice" guidelines

- on translational research, biomarker technologies, biobanking, data stewardship.

2. Efficiently execute high quality biomarker projects

- work together in clinical validation and development of probable biomarkers

EATRIS IMAGING & TRACING PLATFORM

38 European advanced Translational Imaging centres

State-of-the-art technologies and expertise:



- Preclinical and clinical scanners
- PET, MRI (incl. 7T), US, optical
- Multimodal imaging (incl. PET/CT, PET/MRI)
- Nanomedicine formulation contrast agents
- Cyclotrons (all medical radioisotopes)
- Radiochemistry (GMP, >70 tracers)
- Preclinical, translational and clinical expertise
- Handover to industry early dialogue & partnering



EATRIS IMAGING PLATFORM – Technology offering



- Access to new technologies and high-end academic infrastructure
- Early de-risking for drug candidates and therapeutic strategies
- Full development of imaging biomarkers, incl. data analysis
- Target engagement, patient stratification
- Tailored collaboration with pharma and SME clients
- Spur innovation in rare diseases and precision medicine



Educational activities - examples

 NEURATRIS (Paris) – Webinar series in Neuroimaging (Nov 2018): CEST-MRI for neurodegenerative diseases, Optical tools for brain cells, PET imaging to investigate neurodegenerative diseases Next edition, new topics in March 2019



- VHIR (Barcelona) Translational Medicine course for PhDs and Postdocs (Ccomend project) *Financial support by LaCaixa Foundation (next edition Nov 2019)*
- University of Ljubljana PPP Best Practice workshop (Dec 12-13, 2018; CORBEL project)
- TRANSLATION TOGETHER E&T Working group expand E-learning, organize workshops,...



Multi-site Imaging: ⁸⁹Zr PET/CT Accreditation Program

Goal: Enabling multi-center trials with harmonized ⁸⁹Zr PET/CT imaging
Scope: Development of accreditation program with EANM/EARL
Preparation: Pilot phase (n=7) completed in 2017 (incl. EATRIS sites)
Potential scale: >150 eligible sites (already FDG accredited)
Immuno-PET quick start support: IMPD, SOPs, GMP compliance training
Current Status:

- Launch of accreditation program Jan 2019
- Operated by EANM/EARL










Imaging Supporting Pharma Drug Development




Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

A.N. Niemeijer¹, D. Leung², M.C. Huisman³, I. Bahce¹, O.S. Hoekstra³, G.A.M.S. van Dongen³, R. Boellaard³, S. Du², W. Hayes², R. Smith², A.D. Windhorst[®], N.H. Hendrikse³, A. Poot³, D.J. Vugts³, E. Thunnissen⁴, P. Morin², D. Lipovsek², D.J. Donnelly², S.J. Bonacorsi², L.M. Velasquez², T.D. de Gruijl[®], E.F. Smit⁶ & A.J. de Langen¹⁶

Head-to-head comparison of [⁸⁹Zr]-nivolumab and [¹⁸F]BMS986192 in same patients (n=13), against IHC.

Several EATRIS sites involved in industry collaborations


Industry research services



Various collaboration types supported

	Туре	Key success factors	Rate limiting factors	
	Single Service	Matching expertise	Finding the right partner Check: freedom to operate	
	Master Service	Robust platform Client orientation	Successful pilot	
*	Collaborative	Trust Track record	Due diligence Audit(s)	
S. C.	Complex Collaborative	Aligning expectations early Project champion Single point of contact	Project complexity Lack of technical expertise Lack of PM capacity/experience	
Ľ.	Collaboration Hub	Critical mass Long term commitment True collaborative spirit Facilitator/negotiator Administrator	Legal & operational design Slow decision making (private) Priorities, capacity planning (public)	Increi
	(Based on EATRIS ERIC exper	(Pasad an EATRIS ERIC experience 2012 2018)		

Public-Private Innovation Hub



UNIQUE HUB COLLABORATION - IMAGING METHOD DEVELOPMENT IN INFLAMMATORY DISEASES

International multi-site collaboration hub will implement new clinical imaging tools and deliver several projects per year with enhanced speed and throughput.

Amsterdam, The Netherlands, June 4, 2018 – The European Infrastructure for Translational Medicine (EATRIS) has formed a collaboration with GlaxoSmithKline (GSK) to deliver a clinical and scientific expert network for the development and application of innovative imaging methods for inflammatory diseases.




Advanced imaging. The initiative is aimed at optimising existing imaging technologies for drug development and clinical translation of emerging probes.

While existing clinical imaging tools provide useful endpoints in clinical trials, they typically lack sufficient cellular and molecular information to fully understand drug response. Imaging has the potential to interrogate inflammatory cell populations, quantitatively in different tissues. This alliance aims to unlock this potential by delivering new clinical tools. Applying imaging in information-rich, small cohort studies can provide a high, immediate impact to enhance R&D productivity: developing our understanding of disease in the patient; enriching clinical trial cohorts; measuring therapeutic response.

The imaging hub aims to achieve these goals by (1) optimising existing magnetic resonance imaging (MRI) and positron emission tomography (PET) technology

for drug development; and (2) translating emerging PET and optical cell-specific probes towards the clinic. The first three projects with a focus around immune cell specific imaging have now been initiated.



EATRIS SMALL MOLECULES PLATFORM

27 European Academic Drug Discovery centres

State-of-the-art technologies and expertise:



- Drug discovery platforms
 - HTS platforms (incl. X-ray / cellular and organoid screening)
 - Lead finding (MedChem/Pharmacology)
 - In vivo profiling
 - ADME profiling
- Peptide production (incl. GMP)
- Structural analysis (NMR, X-ray, LC/MS)
- (Re-)formulation labs

SMALL MOLECULES PLATFORM - Technology offering

Nanomedicines & Targeted Therapeutics for Precision Medicine

- Optimization of nanoparticle composition for clinical studies
- In vitro and in vivo safety / efficacy / profiling
- Compliant nanoparticle production

Advanced • PDX me • Compo

Advanced Screening


- PDX models for immune oncology
- Compounds collections of existing and novel drugs
- Organoid/ 3D cultures for tumor microenvironment screening
- Set up compliant in vivo models

Drug repurposing

- Chemosensitisers
- Drug synergisms for combination therapies
- Drug sensitivity screening / pharmacoresistance
- ODD designation application support

Quality Initiative: HTS screening

HTS ring-testing programme



Developed by Translation Together, a partnership of:




National Cente for Advancing Translational Sciences



Japan Agency for Medical Research and Development

SYNERGY

H2020 specific challenge "SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders".



HTS (X-ray/chemo), eHealth records, NGS, Machine Learning.

EATRIS ATMP PLATFORM

38 Advanced Therapy Research Centers


State-of-the-art technologies and expertise:

- Preclinical testing capabilities- preclinical animal models
- Genome editing and therapy
- Cell therapy and transplantation,
- Access to patients cohorts eligible for clinical trials with ATMPs
- Access to clinical facilities for carrying out Phase I/II/III clinical trials with ATMPs
- Support for trial design and execution under Good Clinical Practice
- Clinical testing capabilities, including routine as well as specialised clinical analyses, immune-monitoring, clinical imaging,
- Clinical tissue banking operations according to 2004/23/EU
- GMP Manufacturing
- Regulatory Support



What do we do as a Platform?





Supporting our Institutions in Developing

Example: SCIBEC 3289: Regenerative medicine: from new insights to new applications (single-stage call; deadline: April 16 2019)

- Genome editing- CRISPR
- Gene therapy Expertise
- Transdifferentiation and in vivo reprogramming,
- cell therapy and Transplantation
- GMP Production of Cell and Gene Therapy Products
- Organoids
- Clinical Trial Facilities

EATRIS reviewed 8 applications - joined 2 as partner

Driving Funding Calls around key Challenges in ATMP Development



 The ATMP platform participated in an IMI consultation to identify bottlenecks in ATMP development. EATRIS formed a major part in the European Union (EU) wide consultation which resulted in the first ATMP specific calls which will be initiated in 2017/18 where EATRIS will participate in relevant consortia as they arrive.





Addressing Pressing Needs in the Development of Advanced Therapies

David Morrow*, Anton Ussi and Giovanni Migliaccio

EATTHE EFVC, European Infrastructure for Translational Medicine, Amsterdam, Netherlands

September 2017 EATRIS paper "Addressing Pressing Needs in the development of advanced therapies" accepted for publication. This papers promotes the need for an innovation group which involves the funder, industry, regulator and academic RIs to address systemic challenges in ATMP development. (paper circulated at IMI for EATRIS involvement in funding proposal strategy)

New Collaborations to Promote our Platform Resources and Expertise





- Conference/Workshop Development
- Mutual Marketing
- Business Development Activities
- EATRIS Expertise/Services Promotion at Conferences







Educational and Training Initiatives



Workshop D: Potency assays in advanced therapies and vaccines Highlighting the strategy, pitfalls and regulatory pathway for the development of ATMPs and Vaccines

PROGRAMME

16:30 - 16:40	Introduction- Characterisation and Potency Assay strategy - Maria Cristina Galli & Lucia Gabriele (ISS, Italy)
16:40 - 17:00	Regulatory Guidance for Potency Assay Strategy Koen Brusselmans (Belgian Scientific Institute of Public Health) Marcos Timon (Spanish Medicine Authority) Ivana Haunerova (State Institute for Drug Control, Czech Republic)
17:00 - 17:30	Case Study Holoclar- Potency Assay Strategy for Market Approved ATMP - Graziella Pellegrini (Unimore)
17:30 - 18:15	Teams work on cases
18:15 - 19:15	Scientific Advice Meetings
	Panel of 5 regulators 1) Maria Cristina Galli (ISS) 2) Giovanni Migliaccio (EATRIS) 3) Marcos Timon (Spanish Medicine Authority) 4) Ivana Haunerova (State Institute for Drug Control) 5) Koen Brusselmans (Belgian Scientific Institute of Public Health)
19:15 - 19:30	Discussion and Wrap up

Collaboration with industry

Provide access to:

Scientific / medical expertise + technology in ATMP development

We identify academic partners that can offer specific expertise and technology to facilitate ATMP development including:

- Imaging & tracing capabilities
- Specific assays and animal models
- (rare) patient cohorts and samples
- Regulatory support
- GMP Manufacturing
- And much more...



38 EATRIS ATMP Research Centers


Identifying Challenges in the ATMP Field

- Many systemic bottlenecks in ATMP development are due to weak/nonexistent cross-sector cooperation.
 - Accessing latest translational tools, e.g.
 - Molecular imaging (cell tracking for CTs),
 - The right potency assays,
 - Assays addressing collateral effects of new therapies (e.g CRS from ACT)




There exists a real need to develop and validate a quantitative, non-invasive, cell imaging platform for cell therapies

- EATRIS Flagship Project-




Cross-sectoral collaboration is a critical success factor

Lack of basic knowledge of CAR T cell behavior in vivo



Ţ



CAR T cell biodistribution?


Cell numbers at tumor?

Proliferation at tumor site?

Tumor infiltration?

How can we acquire a comprehensive picture, noninvasively, of what is happening in vivo with promising therapeutic cells?

Ę




SC1-BHC-09-2018:Innovation platforms for advanced therapies of the future -Level 4 Support-


What does the EPPIC Project want to deliver?

EPPIC foresees the close interaction of academic, clinical and industrial partners, and wishes to pursue a number of activities with diverse outcomes. It is envisaged that planned activities will deliver:

Objective:

Develop a broadly applicable platform, which incorporates noninvasive in vivo imaging and predictive modelling for the optimization of cell therapies, that is integrated into existing ATMP supply chains.







The Partners



Scientific Advisory Board

EATRIS Vaccine Platform

15 Participating Centers

State-of-the-art technologies and expertise:

- Antigen Production/Delivery Systems
- Preclinical Animal Models
- Vaccine Production Facilities
- Immunomodulation and Immunomonitoring Platforms for Vaccine Candidates
- Access to Patients Cohorts eligible for Clinical Trials with Vaccines
- Access to clinical facilities for carrying out Phase I/II/III Clinical Trials with Vaccines
- GMP Manufacturing
- Regulatory Support



EATRIS Vaccine Platform Initiatives





IPROVE: The "Innovation Partnership for a Roadmap on Vaccines in Europe", financed under the EU 7th Framework Programme in which EATRIS was one of the partners, was launched setting out a vision for vaccine rese-arch and innovation in Europe over the next 20 years. (Now Published)

EURIPRED is a collaborative infrastructure program, its objective the reinforcement of the knowledge infrastructure across diseases. Its aim is to speed the development of new tools (vaccines, drugs, microbicides) to combat tuberculosis, human immunodeficiency virus (HIV), malaria, hepatitis B virus (HBV) and hepatitis C virus (HCV). One of the key activities is providing reference reagents, services and trainings for free. (Ends in Oct 2017- Reagents still available)



TRANSVAC2 (2017-22) is a collaborative infrastructure project funded by the <u>European Commission</u> (EC), first under the <u>7th Framework Programme</u> (FP7) and currently under <u>Horizon 2020</u>. The project is a joint effort of leading European groups in the field of vaccine development, and is coordinated by the <u>European Vaccine</u> <u>Initiative (EVI)</u>. TRANSVAC is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development. EATRIS makes up one of the 25 partners in this initiative which Kicked off in May 2017.

Offering Technology Platforms for New Vaccine Candidates.

- CD8 T-cell responses for vaccine candidates
- Mucosal immunity and vaccines
- Th1 and Th2 vaccine-induced immunity
- Long term immune memory
- Safety and tolerability-development of biomarkers of safety and protection from the bedside to the bench
- RNA vaccines
- Innovative clinical trials

Thank you for your attention and your engagement in Q&A

For further information



davidmorrow@eatris.eu martindekort@eatris.eu antonussi@eatris.eu Example Projects in the EATRIS Portfolio

Biomedical cluster project (until 2020)





"By harmonising user access, unifying data management, creating common ethical and legal services, and offering joint innovation support CORBEL will establish and support a new model for biological and medical research in Europe."

http://www.corbel-project.eu

CORBEL WP8 - fostering RI innovation potential

- Innovation office to be sustained after CORBEL
- Real time partnering & collaboration advice for RIs open daily
- Template documents, guidelines and assistance with collaboration and knowledge sharing;
- Access to specialist knowledge in relation to business development and legal, regulatory or ethical aspects;



European Joint Programme in Rare Disease

Multi-stakeholder, patient-centred initiative to foster rare disease research from bench to bedside and back - 5 years, €108 million

EJP-RD goals include:

- structuring the connection with European Reference Networks;
- research funding (E-RARE ERA-NET);
- promoting improved research methodologies for rare disease research;
- More effective translation and professional mentoring;
- ensuring **patient involvement** in all steps of the research pathway;
- FAIR principles (Findable, Accessible, Interoperable, Re-usable);

EATRIS leads Pillar 4 (translation & clinical) & Sustainability

Early HTA & Feasibility Assessment

EATRIS developed early HTA framework for ZonMw

- For Translationeel Adult Stamcelonderzoek programme 2018
- Uses EUNetHTA 9 point model plus EATRIS principles

Working with Reuma Nederland and ZonMw since 2014

- Assessing translational feasibility of translational research projects
 - Unmet medical need
 - IP status
 - Technological novelty (competitive landscape)
 - Regulatory pathway





Establishing pan-EU access to high quality infrastructure



GSK - Immuno inflammation Imaging Hub


- Next generation public-private collaboration
- Translating new molecular inflammation imaging targets and probes to humans



Press Release, June 2018

Enabling multi-sector innovation

- Identify systemic bottlenecks
- Develop new ways to fund/collaborate
- Work directly with charities/funders
- Work directly with regulators





Bring together expertise to help select and design validation of biomarker study for early cancer detection





Designed early HTA framework For €8mn call financed by Min. Health For more patient-centric, affordable innovation

Enabling multi-sector innovation: Human + Social venture capital, 21 charities and EATRIS-ERIC collaborating for better patient outcomes

human⁺



- 1- All NL health charities & ZonMw can apply for VC co-funding (33%)
- 2- EATRIS performs feasibility assessment
- 3- Human+ Investment Board decides on funding
- 4- EATRIS supports execution as needed

Working with global with peers – Translation Together








(0.3)











Japan Agency for Medical Research and Development



BOUNDARY CROSSER

fracks down disriplinary sites and collaborates with

TEAM PLAYER Practices a term whereas opposed, by been spire the strengths and separtise and valving the contributions of all players on the translational science team.

others across research areas and professions to collectively odvance the planelagment of a medical intervention.

CHARACTERISTICS OF A TRANSLATIONAL SCIENTIST

Translation is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public - from diagnostics and therapeutics to medical procedures and behavioral changes. The professionals involved in this process, wither developing interventions or improving the process Itell, are TRANSLATIONAL SCIENTISTS.

RIGOROUS RESEARCHER Conducts research at the highest levels of right and transportency, possesses strong autistical analysis skills, and designs research projects to meaining reproducibility.

PROCESS INNOVATOR its to bottor understand the accentile and operational principles and onlying the translational process, and innovates to overcome batterecks and accelerate that process.

DOMAIN EXPERT cenerals deep disciplinory knowledge and expertise within one or more of the domains of the translational science spectrum ranging from basic to clinical to public health research and domains in between

Developed by Statulation Reputies, a permarable of


rdrd eatris

Objectives



Coordinate and develop next generation of translational scientists and other key stakeholders.






Ø development of medical interventions, including patient rands and prelements.



regulatory requirements, convert atordards of care, and market and husiness demands.

Working with global with peers – EATRIS Quality Initiative

HTS Ring Testing



Explore reproducibility of HTS experiments - identify sources of variation among participating centers:

- Blinded library of Pharmacologically Active Compounds luciferase biochemical assays with Photinus pyralis and Renilla reniformis
- All experiments are performed with identical reagents and protocols supplied by NCATS
- All data analyses performed at NCATS as well as each participant individually